1. Adverse drug reactions, adherence, and virologic outcomes in adult patients on dolutegravir-based antiretroviral therapy at a tertiary hospital, southeast Nigeria.
- Author
-
Ogbonnaya LU, Onah CK, Azuogu BN, Akpa CO, Okeke KC, Nwachukwu VN, Stephen-Emeya A, Asaga IU, and Umeokonkwo CD
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Adult, Nigeria, Viral Load, Treatment Outcome, Oxazines, Pyridones, Heterocyclic Compounds, 3-Ring adverse effects, Heterocyclic Compounds, 3-Ring therapeutic use, Piperazines, HIV Infections drug therapy, Tertiary Care Centers, HIV Integrase Inhibitors therapeutic use, HIV Integrase Inhibitors adverse effects, Body Mass Index, Assessment of Medication Adherence
- Abstract
Objective: To assess the adherence, adverse drug reactions (ADR), and virologic outcomes of dolutegravir-based antiretroviral therapy., Design: This was a retrospective chart review., Setting: A tertiary health facility-based study in Abakaliki, Nigeria., Participants: Five hundred and fifteen (515) adult patients on dolutegravir were selected using a Random Number Generator. Demographic and clinical data were extracted from patients' case notes and analysed with IBM-SPSS version-25., Main Outcome Measures: Adherence to dolutegravir, ADRs, virologic outcome, and change in Body Mass Index (BMI) were estimated., Results: The mean age of the patients was 45.5±10.8 years; 68.2% of them were females; 97.1% of them had good self-reported adherence. The majority (82.9%) of them reported no ADRs and among those (17.1%) that did, headache (9.7%), body-itching (3.1%), and skin rash (2.7%) dominated. Most achieved viral suppression (94.4%) and did not have detectable viral particles (57.4%). There was a significant increase in the BMI of the patients with a mean weight increase of 0.9kg, a mean BMI increase of 0.3 kg/m
2 , and a 2.6% increase in the prevalence of overweight and obesity., Conclusions: Patients on dolutegravir reported low ADRs, good self-reported adherence, and a high viral suppression rate. However, dolutegravir is associated with weight gain. We recommend widespread use and more population-wide studies to elucidate the dolutegravir-associated weight gain., Funding: None declared., Competing Interests: Conflict of interest: None declared., (Copyright © The Author(s).)- Published
- 2024
- Full Text
- View/download PDF